Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
第一著者: | |
---|---|
その他の著者: | |
フォーマット: | 学位論文 |
言語: | English |
出版事項: |
Brac University
2024
|
主題: | |
オンライン・アクセス: | http://hdl.handle.net/10361/23271 |
id |
10361-23271 |
---|---|
record_format |
dspace |
spelling |
10361-232712024-06-09T21:03:52Z Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study Karmaker, Swastika Yasmin, Hasina School of Pharmacy, Brac University Alzheimer’s disease Rhabdomyolysis Galantamine Dementia Alzheimer's disease Dementia Neuropharmacology This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from PDF version of thesis. Includes bibliographical references (pages 38-42). Galantamine is one of the common acetylcholinesterase inhibitors used to treat Alzheimer's disease, a neurodegenerative disorder. This study was conducted to determine the impact of galantamine on mortality rate and rhabdomyolysis using the FDA Event Reporting System(FAERS) database, which includes data from drug class and the whole database. Comparing the mortality rate of galantamine to that of other drugs and other class, it was found that 24 deaths were recorded on FAERS, compared to 456,120 and 680 deaths for other drugs and drug class, respectively. In this analysis, galantamine showed better mortality benefit than others. The ROR value of death cases for other drugs was 1.22(95%CI:0.81-1.83;p=0.3435) vs. drug class 0.31(95%CI:0.21-0.47;p<0.0001). Furthermore,8 rhabdomyolysis cases were recorded in FAERS, while 16379 and 19 cases were reported on other drugs and other class, respectively. It has been found that galantamine is more likely of causing rhabdomyolysis than other drugs. The Reporting Odds Ratio (ROR) value for rhabdomyolysis for other drugs was 11.35 (95%CI:5.65-22.80; p<0.0001) vs drug class 4.05(95%CI:1.77-9.29; p=0.0009). Swastika Karmaker B. Pharmacy 2024-06-09T09:21:02Z 2024-06-09T09:21:02Z ©2023 2023-02 Thesis ID 18346089 http://hdl.handle.net/10361/23271 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 54 pages application/pdf Brac University |
institution |
Brac University |
collection |
Institutional Repository |
language |
English |
topic |
Alzheimer’s disease Rhabdomyolysis Galantamine Dementia Alzheimer's disease Dementia Neuropharmacology |
spellingShingle |
Alzheimer’s disease Rhabdomyolysis Galantamine Dementia Alzheimer's disease Dementia Neuropharmacology Karmaker, Swastika Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study |
description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. |
author2 |
Yasmin, Hasina |
author_facet |
Yasmin, Hasina Karmaker, Swastika |
format |
Thesis |
author |
Karmaker, Swastika |
author_sort |
Karmaker, Swastika |
title |
Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study |
title_short |
Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study |
title_full |
Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study |
title_fullStr |
Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study |
title_full_unstemmed |
Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study |
title_sort |
signal detection of rhabdomyolysis and death for galantamine: a pharmacovigilance study |
publisher |
Brac University |
publishDate |
2024 |
url |
http://hdl.handle.net/10361/23271 |
work_keys_str_mv |
AT karmakerswastika signaldetectionofrhabdomyolysisanddeathforgalantamineapharmacovigilancestudy |
_version_ |
1814308715000496128 |